Compare RM & TMCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | TMCI |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 279.6M |
| IPO Year | 2011 | 2021 |
| Metric | RM | TMCI |
|---|---|---|
| Price | $32.62 | $4.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $4.77 |
| AVG Volume (30 Days) | 101.6K | ★ 392.8K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ 7.49 | N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $645,598,000.00 | $212,690,000.00 |
| Revenue This Year | $12.94 | N/A |
| Revenue Next Year | $8.97 | $8.18 |
| P/E Ratio | $16.10 | ★ N/A |
| Revenue Growth | ★ 9.70 | 1.59 |
| 52 Week Low | $30.46 | $1.17 |
| 52 Week High | $46.00 | $7.46 |
| Indicator | RM | TMCI |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 52.26 |
| Support Level | $33.51 | $3.84 |
| Resistance Level | $35.43 | $4.67 |
| Average True Range (ATR) | 0.98 | 0.27 |
| MACD | 0.25 | -0.01 |
| Stochastic Oscillator | 60.16 | 43.42 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. The company is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.